



JPMA

Journal of the
Pakistan Medical Association (Centre)

Editorial Board

Chairman

Shahid Ahmed Sami

Editor-in-Chief

Fatema Jawad

Associate Editor-in-Chief

Huma Qureshi

Associate Editors

Qudsia Anjum Fasih

Sina Aziz

Syed Muhammad Mubeen

Editor Students' Corner

Maryam Farooqui

Statistical Reviewer

Syed Muhammad Zulfiqar Hyder
Naqvi

Managing Secretary

Anwar Ali Khawaja

Administrative Secretary

Ahmed Abdul Majid

MEMBERS

Aamir Raof Memon
Aamna Hassan
Aisha Mehnaz
Ali Yawar Alam
Anwar Ali Siddiqui
Asif Khaliq
A.R. Jamali
Bushra Shirazi
Farooq Azam Rathore
Fehmina Arif
Gulnaz Khalid
Muhammad Iqbal Afridi
Khalid Zafar Hashmi
Kiran Ejaz
Manzoor Hussain
Masood Ali Shaikh
Mehwish Kashif

Mirza Naqi Zafar
Mohammad Wasay
Muhammad Shahzad Shamim
Syeda Nosheen Zehra Zaidi
Ramsha Zaheer
Rehman Siddiqui
Rubina Naqvi
Rumina Hasan
Sadiah Ahsan
Muhammad Shahid Shamim
Syed Sharaf Ali Shah
Sohail Akhtar
Syed Mamun Mahmud
Uzma Fasih
Zakiuddin G. Oonwala
Zubaida Masood

INTERNATIONAL ADVISORS

Ahmed Badar (KSA)
Amin Ali Muhammad Gadit
(CANADA)
Farhad Handjani (IRAN)
Farrokh Habibzadeh (IRAN)
Gerry Mugford (CANADA)
Itrat Mehdi (OMAN)
MEL Heyman (USA)
Mohammad Bagher Rokni (IRAN)
Mubeen Rafay (CANADA)

Mihnea Alexandru Gaman
(ROMANIA)
Osman Faruk Bayramlar (TURKIYE)
Sanjay Kalra (INDIA)
Shabih Zaidi (UK)
Sultan Ayoub Meo (KSA)
Tanveer Azher (CANADA)
Tahir Masood (KSA)
Zohra Zaidi (UK)

Articles published in JPMA do not represent the views of the Editor or Editorial Board.
Authors are solely responsible for the opinions expressed and accuracy of the data.

The Journal of Pakistan Medical Association (JPMA) is published monthly from PMA House, Aga Khan III Road, Karachi-74400, Pakistan.

All articles published represent the opinion of the authors and do not reflect official policy of the journal. All rights reserved to the Journal of the Pakistan Medical Association. No part of the Journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical photocopying, recording or otherwise, without prior permission, in writing, of the Journal of the Pakistan Medical Association.

Price: Rs.2200/- (Single Issue)

Annual Subscription: 26,000/- in Pakistan and US\$500.00 for overseas countries (including air mail postage).

Publication Office: PMA House, Aga Khan III Road, Karachi-74400, Pakistan. Telephone: 92-21-32226443.

E-mail: editor@jpma.org.pk

FOREWORD FOR NATIONAL PPH GUIDELINES FOR PAKISTAN

PPH remains the leading cause of maternal mortality in Pakistan, yet there were no existing national guidelines. NCMNH (National Committee for Maternal and Neonatal Health) and its partner AMAN (Association for mothers and Newborns), realizing this gap along with its partners and stakeholders, have produced an evidence based document for use throughout Pakistan by its health workers providing maternity care. Leading Obstetricians & Gynaecologists of the country as well as Stakeholders have reviewed the document and approved it for its practical guidance and implementation.

We are particularly grateful to international experts, Emeritus Prof. Sir Sabarathnam Arulkumaran, Prof. Arri Coomarasamy, and Dr Ioannis Gallos and our National experts Prof Sadiyah Ahsan Pal , Dr Shahida Zaidi, Dr Azra Ahsan, Prof Razia Korejo, Prof Rizwana Chaudhri , Prof Lumaan Shaikh, Assoc Prof Sidra Nausheen, Assoc. Prof Nausheen Farooq, Prof Rehana Rahim, Prof Shamsa Humayun, Prof Sadaqat Jabeen, Prof Naila Ehsan, Prof Syeda Batool Mazhar, Prof Rubina Sohail, Prof Shahida Sheikh, Prof Mohd Tayyab, Prof Maj Gen Abeera Chaudhry, Prof Haleema Yasmin, Prof Zahida Perveen, Prof Shahid Rao, Dr Maryam Zubair, Dr Shams Rashidi and Dr Qudsia Uzma for their efforts for placing these guidelines together. We would also like to acknowledge the permission granted to use the PPH Bundle posters and charts for this guideline and our trainings, by Prof Thomas Burke & his team at Massachusetts General Hospital, USA.

We hope this document will not only guide but also help in reducing the morbidity and mortality from PPH through better organized "Bundle approach management"
Best wishes from the NCMNH & AMAN Team.

**THIS GUIDELINE IS REVIEWED BY:
(BASED ON THE WHO AND FIGO RECOMMENDATIONS 2022, WHO MCPC
MANUAL 2017 (UPDATED PAKISTAN EDITION 2023, IN PRINTING PROCESS))**

**Emeritus Prof. Sir Sabarathnam Arulkumaran
OBE, FRCOG, Past President RCOG, FIGO**

**Prof. Arri Coomarasamy
OBE, MBChB, MD, FRCOG, FMedSci
University of Birmingham, UK, Birmingham Women's Hospital, UK**

**Dr Ioannis Gallos
DMS, MD, MRCOG, Consultant SRH WHO**

Guideline Development Group

Prof Sadiah Ahsan Pal

FRCOG (Vice President AMAN, Technical Consultant NCMNH, Member Academic Board SOGP, Chairperson Maternal and Perinatal health Committee SOGP)

Dr Shahida Zaidi

FCPS, Vice President AMAN, Senior Technical Consultant NCMNH, Ex-Vice President FIGO

Dr Azra Ahsan

FRCOG, Vice President NCMNH, President AMAN, member Academic Board SOGP

Prof Razia Korejo

FCPS, Baharia Medical College, Karachi. (Ex-President, Executive Member and Academic Board member of SOGP, Exec Member NCMNH and AMAN)

Prof Rizwana Chaudhri

FCPS, (Medicare Hospital Rawalpindi)

Prof Lumaan Shaikh

FRCOG, Chairperson OBGYN (AKUH), Karachi

Assoc Prof Sidra Nausheen

FCPS, OBGYN (AKUH) Karachi

Assoc. Prof Nausheen Farooq

FCPS, HOD OBGYN (Polyclinic, Islamabad)

Prof Rehana Rahim

FRCOG, LRH, Peshawar (Secretary Academic Board SOGP)

Prof Shamsa Humayun

FCPS, SGRH, Lahore (Ex Vice President SOGP, Member Academic Board SOGP).

Prof Sadaqat Jabeen

FCPS, LRH, Peshawar. (Academic Board member SOGP)

Prof Naila Ehsan

FCPS, Quetta (Academic Board member SOGP)

Prof Syeda Batool Mazhar

FCPS, Islamabad (President SAFOMS, Member Academic Board SOGP)

Prof Rubina Sohail

FCPS, RLMC Lahore (Past President SAFOG, past Executive member SOGP)

Prof Shahida Sheikh

FCPS, Chairperson SZMU, Larkana (Exec member SOGP)

Prof Mohd Tayyab

FRCOG, FCPS, Lahore, Ex Vice president and Member Academic Board SOGP, Council Faculty CPSP

Prof Maj Gen Abeera Chaudhry

FRCOG, FCPS, HOD, AMC, Rawalpindi, Faculty CPSP

Prof Haleema Yasmin

FCPS, Chairperson OBGYN, JPMC, Karachi, Exec member and Former Sec Gen SOGP

Prof Zahida Perveen

FCPS, Ayub teaching hospital, Abbottabad, Faculty CPSP, Joint Secretary SOGP

Prof Shahid Rao

FCPS, Nishtar Hospital Multan, Academic Board and Executive member SOGP

Dr Maryam Zubair

FCPS, Muzaffarabad AJK (Academic Board Member SOGP)

Dr Shams Rashidi

FCPS, Consultant Anaesthetist, Concept Fertility Centre, New Beginnings Karachi

Dr Qudsia Uzma

WHO, Pakistan

Acknowledgements:

For technical assistance with this guideline

Dr Humera Mansoor

(AMAN, NCMNH)

Mr K M Babar Pal

(AMAN)

Dr Maryam Iqbal

(AMAN)

Dr Mariam Waqas

(NCMNH, AMAN)

NATIONAL GUIDELINES FOR THE MANAGEMENT OF POST-PARTUM HAEMORRHAGE (PPH) FOR PAKISTAN- JULY 2023

National Committee for Maternal and Neonatal Health (NCMNH) and Association for Mothers and Newborns (AMAN)

Introduction

This guidance is evidence based, peer reviewed and will be updated as newer practice changing evidence.

Post Partum Haemorrhage (PPH) is the leading cause of maternal death in Pakistan and worldwide¹⁻³. In depth analysis of Maternal deaths in Pakistan⁴, reveals Obstetric Haemorrhage as the leading cause (65/160 Direct Maternal Deaths) (41%). Amongst the deaths due to obstetric haemorrhage, PPH accounted for 50 deaths (89%) and antepartum haemorrhage (APH) accounted for 15 (11%) deaths³.

Highest number of deaths due to obstetric haemorrhage were reported in Gilgit Baltistan (GB) (58%) and Khyber

Pakhtunkhwa (KP) (56%) followed by Baluchistan (48%), Punjab (38%), Sindh (29%) and Azad Jammu & Kashmir (AJK) (20%)³. Among the 50 deaths due to PPH, 48 (96%) had primary PPH and 2 (4%) had secondary PPH. Uterine inertia was responsible for 33(69%) (Fig 2) deaths due to primary PPH³, as reported in Explaining Maternal Mortality: An In- depth Analysis of Pakistan Maternal Mortality Survey (PMMS)- 2019, for deaths that occurred 3 years prior to this survey.

Pakistan's Maternal Mortality Ratio (MMR) has come down to 186 per 100,000 live births¹. Pakistan Maternal Mortality Survey (PMMS)- 2019, for deaths that occurred 3 years prior to this survey.




Figure-1: Causes of Maternal Deaths in Pakistan




Figure-2: Maternal Deaths due to Primary Postpartum Haemorrhage (n=48).

An In-depth analysis of this report reveals that neglect and poor management in health facilities also contributed to these deaths. Misadventures contributed to 93 deaths i.e.36% of the total 259 maternal deaths, and to (75%) of the 50 deaths due to PPH.

Most deaths occur within 2 hours of delivery. Rapid action is critical for survival. Majority of women who experience PPH have no risk factors. Early recognition of this condition may result in saving many lives. Recent scientific evidence and new technological developments have necessitated changes to the management of PPH in Pakistan in line with the guidelines from World Health Organisation,⁵ International Federation of Gynaecology & Obstetrics (FIGO),⁶ American College of Obstetricians and Gynaecologists (ACOG),⁷ Royal College of Obstetricians and Gynaecologists RCOG,⁸ Federation of Obstetric and Gynecological Societies of India (FOGSI)⁹ and other major International Obstetrics and Gynaecological professional bodies. PPH guidelines using Bundle approach⁵⁻¹⁰ of management with early detection, have helped improve the care of women around the world and their use should be followed in all health facilities in Pakistan as well.

Care bundles approach of management have been associated with improved patient outcomes. The goal of the PPH bundle is to reduce the frequency of severe haemorrhage and improve maternal outcomes. The shock index indicator, defined as the ratio of heart rate to systolic blood pressure (HR: SBP), is simple to use, and has better predictive ability than other vital signs because it detects acute changes in the maternal cardiovascular system and acts as an early marker to predict adverse outcomes. Anyone who attends a birth can be taught simple home-based life-saving skills.

Evidence-based prevention and management of PPH can

be achieved with the early accurate measurement of blood loss, and timely treatment,^{11,12} Early detection of PPH treatment triggers, include the use of Calibrated drapes for the collection of blood, with trigger lines at 300 ml and 500 ml for the first hour after birth.

Calling the 1st Bundle "MOTIVE" may help practitioners to help recall all the components, and not forget to give something (MOTIVE: Uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids, and Examination or Establish Cause and Escalation)

Post partum monitoring of blood loss, blood flow, uterine tone every 15 minutes documented on the blood-loss monitoring chart along with Blood Pressure and pulse monitored once in the first hour post-partum. Trigger Criteria (emotive)¹¹ for treatment include clinical judgment of blood loss ≥ 500 ml, or blood loss ≥ 300 ml plus one abnormal observation.

Any amount of bleeding after childbirth which causes cardiovascular compromise/ deterioration of vital signs should be considered PPH.

Primary Postpartum Haemorrhage (PPH) is defined as blood loss > 500 mL within 24 hours after birth. Secondary PPH is > 500 mls blood loss after 24 hours of childbirth.^{5,8}

Further subdivisions are:

Minor PPH: 500-1000 mls
 Moderate PPH: 1000-2000 mls
 Severe PPH: 2000 mls or more

Problems with these definitions:

- Estimates of blood loss are notoriously low, often half the actual loss. Blood can be mixed with amniotic fluid and urine. It is dispersed on sponges, towels and linens, in buckets, and on the floor.
- The importance of a given volume of blood loss varies with the woman's haemoglobin level before she gives birth. A woman with a normal haemoglobin level will tolerate blood loss that would be fatal for an anaemic woman. Anaemic women collapse and die from hypotension, therefore avoid hypotension with early insertion of a 14 G or 16 G IV cannula and fluid/ blood replacement.
- Bleeding can occur at a slow rate over several hours; the condition might not be recognized until the woman is suddenly in shock. Risk assessment in the antenatal period does not effectively predict which women will have PPH.
- Even healthy, non-anaemic women can have catastrophic blood loss.
- Trigger for initiating treatment is blood loss of 500mls, or earlier at 300 mls + one abnormal

observation.

- We cannot predict who will experience PPH on the basis of risk factors alone.

Risk Factors: Over distended uterus (Twins, big baby, Polyhydramnios), Prolonged labour, antepartum haemorrhage (APH), Severe Pre-eclampsia / Eclampsia, Prolonged intrauterine death, C-section, previous C-section and Anaemia.

Causes of PPH include: Uterine atony (most common), retained placenta or fragments, tears of uterus, cervix, vagina, perineum, coagulation defects, inversion of uterus, infection (delayed PPH).

PPH prevention

Antenatal Care should include minimum 8 contact visits, prevention, early detection and treatment of Iron deficiency Anaemia and Thalassaemia

AMTSL (Active management of third stage of labour):

Uterotonics for prevention of PPH during the third stage of labour is recommended for all births. *Oxytocin* (10 IU IV/IM) is the preferred uterotonic. *Oxytocin* cold chain should be maintained.

In settings where oxytocin is unavailable or its quality cannot be guaranteed, other injectable uterotonics (if appropriate *Ergometrine/Methylergometrine* 200 µg IM/IV); hypertensive disorders should be excluded prior to its use and cold chain maintained) or *Misoprostol* 400–600 µg orally (heat stable) or *Carbetocin* 100 µg IM/IV (heat stable) is recommended for the prevention of PPH.

The combinations of *ergometrine* + *oxytocin* or *misoprostol* + *oxytocin* may be more effective uterotonic drug strategies for the prevention of PPH ≥500 ml compared with the current standard, oxytocin. This

comes at the expense of a higher risk of adverse effects (vomiting and hypertension with ergometrine and shivering, fever with misoprostol).

In settings where skilled birth attendants (SBAs) are not present to administer injectable *uterotonics*, and *oxytocin* is unavailable, the administration of *Misoprostol* (400–600 µg orally) by community healthcare workers and lay health workers is recommended for the prevention of PPH.

In settings where skilled birth attendants are unavailable, *controlled cord traction* (CCT) is not recommended.

Sustained uterine massage is not recommended as an intervention to prevent PPH in women who have received prophylactic oxytocin.

Postpartum per-abdominal uterine tone/ contraction assessment for early identification of uterine atony is recommended for all women.

Oxytocin (IV or IM) and CCT is the recommended method for removal of the placenta for the prevention of PPH in vaginal and caesarean delivery. The Cord clamping should be delayed for >2 minutes and wait for signs of placental separation with CCT.

Postpartum Care: Women should be monitored closely (every 15 min) during the first hour after delivery, check vaginal bleeding (accurate blood loss measurement), uterine tone, pulse and BP.

Methods of blood loss assessment (usually underestimated)

1. Measure blood loss with Under the buttock drapes
It is best to roll out (ie open the) the funnel of the calibrated under the buttock drape after the birth of the

Postpartum monitoring (PPM) is recommended to ensure early identification and intervention in the case of complications.



Recommended checks:

- Airway and breathing
- Circulation (blood pressure, pulse)
- Vaginal bleeding
- Uterine tone
- Consciousness/convulsions
- Abdominal pain
- Temperature



Recommended timing:

- Every 15 minutes from 0-1 hours after delivery
- Every hour from 1-4 hours after delivery
- Every 4 hours from 4-24 hours after delivery
- Conduct more thorough assessments at 1 hour and discharge

Source WHO integrated management of pregnancy and childbirth guideline 2014

Figure-2: Post Partum Monitoring




Figure-4: Calibrated under the buttock drape for accurate blood loss measurement.

baby, but before the delivery of the placenta (to avoid amniotic fluid collecting in the drape and causing error in measurement).

2. Visual Assessment (Approximate not accurate):

Soaked sanitary towel: 50-100ml.

Kidney tray full: 500ml

Soaked sheets and clothes: 1000 to 1500mls

Blood on floor as well as bed sheets: >2000mls

3. Weighing swabs/ pads (1g = 1 ml)

Weight of wet swabs in grams minus weight of dry swabs in grams = blood loss in mls.

Responding to PPH emergency

Responding to an emergency promptly and effectively requires that members of the clinical team know their roles and how the team should function. Organize an Obstetrics rapid Response Team (ORRT) in every duty shift. Team members should also know clinical situations, their diagnoses and treatments; medicines, how to use and their side effects; emergency equipment and how it functions.

The ability of a facility to deal with emergencies should be assessed and reinforced by frequent practice / simulation emergency drills.

When managing an emergency:

- Introduce yourself.
- Ask the woman her name; if she is unconscious, ask for the woman's name from her companion.
- Encourage the companion to stay with the woman.
- Explain all procedures; ask permission and keep the woman informed as much as you can about what you are doing. If the woman is unconscious, talk to her companion.
- Ensure and respect the woman's privacy during examination and discussion. (Respectful maternal care)

- Do not leave the woman unattended.
- Ensure that the emergency transport the woman used to get to the health facility is retained at the facility until a clear plan of management is in place.

PPH Treatment

Treatment should start with the "Bundle approach". Use an under the buttock plastic drape for accurate measurement of blood loss with early detection of PPH. Action should be taken with 300 mls or even less blood loss when a woman is already anaemic (Do not wait for 500 mls blood loss).

First action is Call for help and start Uterine massage

Above is the PPH management flow chart using prevention, Active management of third stage of labour (AMTSL), early detection and bundle approach

- IV Oxytocin alone is the recommended first-line uterotonic drug for the treatment of PPH
- Oxytocin regimen recommended in E-MOTIVE: 10 units in 500 mls normal saline, given rapidly (ie the bolus), over 10 mins (maintenance regimen: 20 units in 1000 mL normal saline, given over 4 hours)
- If oxytocin is not available, or if the bleeding does not respond to oxytocin, the use of IM ergometrine, oxytocin-ergometrine fixed dose (avoid in cardiac and hypertensive patients), or a prostaglandin (including sublingual misoprostol, 800 µg) is recommended
- There is no evidence about the safety and efficacy of an additional 800-µg dose of misoprostol for treatment of PPH, to women who have already received 600 µg of prophylactic misoprostol orally.
- IV isotonic crystalloids are recommended in preference to the use of colloids for the initial IV fluid resuscitation of women with PPH
- Early use of IV Tranexamic acid (TXA) as soon as PPH




Figure-5: PPH Bundle Management Flow Chart

is diagnosed but within three hours of birth in addition to standard care with clinically diagnosed PPH. 1g (100 mg/ml) tranexamic acid slow IV at 1 ml/min (over 10 min); 2nd dose of 1g IV if bleeding continues after 30 min, or if bleeding restarts within 24 h of completing the first dose. Caution: Do not mix TXA in the same infusion bag as Oxytocin as it may lead to decreased efficacy.

- Intramuscular TXA inhibits fibrinolysis within 10 minutes and may be a suitable alternative to IV TXA when the Birth attendant is not skilled to give IV medication. IM TXA has been shown to be beneficial in prospective studies and is being studied in larger trials.¹³

Initial Management when a woman presents with PPH:

- Stay calm. Think logically and focus on the needs of the woman.
- Take charge. Avoid confusion by choosing one person to be in charge.
- SHOUT FOR HELP. Have one person go for help and have another person gather emergency equipment and supplies (e.g. oxygen cylinder, emergency kit).
- If the woman is unconscious, assess the airway, breathing and circulation. Begin resuscitation of the woman, as needed (e.g., assist breathing, start intravenous infusion).
- Early detection of shock (e.g using the Shock Index

and Rule of 30)⁶ Fig 6.

- If shock is suspected, immediately begin treatment. Even if signs of shock are not present, keep shock in mind as you evaluate the woman further, because her status may worsen rapidly. If shock develops, it is important to begin treatment immediately.
- Position the woman lying down on her left side with her feet elevated. Loosen tight clothing.
- Talk to the woman and help her stay calm. Ask her or someone with her what happened, what symptoms she is experiencing and when they started.
- Perform a rapid evaluation of the woman's general condition, level of consciousness, presence of anxiety and/or confusion, blood loss, colour, and temperature of skin
- Put in one or two large-bore IV cannula/needles. (14 G gives 240 ml/min, 16 G gives 180 ml/min)
- Get blood samples before infusing IV fluids and for the Bedside Clotting test.
- Infuse IV fluids. Adjust the flow rate based on the woman's condition and potential risks of fluid overload (e.g. pre-eclampsia).
- Perform a rapid targeted history and physical examination to make a differential diagnosis of the problem.
- Stabilize the woman.
- Catheterize for monitoring urinary output and prevent a distended bladder
- Document history, findings, actions and plan for

continued management

Basic principles when providing respectful care

- Where feasible, ensure that the woman has a companion of her choice with her.
- Provide information to the woman and any accompanying family members, if the woman would like to be involved in decision-making— about diagnostic tests to be performed, supportive care to be provided (e.g. IV infusion), the process of care, her diagnosis, treatment options and the estimated time for in-patient care if required.
- If the woman is unconscious, explain the procedure to her family.
- Obtain informed consent for any procedures (diagnostic or therapeutic)
- If the woman is in shock, avoid using plasma substitutes (e.g. dextran). There is no evidence that plasma substitutes are superior to normal saline in the resuscitation of a woman in shock, and dextran can be harmful in large doses. Ringer's lactate or Hartmann's are the preferred initial IV fluids for resuscitation
- If a peripheral vein cannot be cannulated, perform a venous cut-down

Infection prevention and control

- Consider every person (woman or staff) as potentially infectious.
- Hand washing is the most practical procedure for preventing cross-contamination.

- Wear gloves before touching anything wet broken skin, mucous membranes, blood or other body fluids (secretions or excretions).
- Use barriers (e.g., protective goggles, face masks or aprons) if splashes and spills of any body fluids (secretions or excretions) are anticipated.
- Use safe work practices such as not recapping or bending needles, proper instrument processing, and proper disposal of medical waste.⁸

Medications used in PPH

Note, all of these drugs (given below) are available in Pakistan except Carbetocin and Carboprost (has excessive side effects). Ergometrine is registered but not available at present. Caution to be practiced in cases with Hypertension.

Clinical use of blood, blood products, and replacement fluids

It is important to be aware of the principles designed to assist health workers in deciding when (and when not) to transfuse Blood.

The appropriate use of blood products is defined as the transfusion of safe blood products to treat a condition leading to significant morbidity or mortality that cannot be prevented or managed effectively by other means.

Conditions that might require blood transfusion include:

- Postpartum haemorrhage leading to shock.
- Loss of a large volume of blood at operative birth.

Table 1: First action is uterine massage, maintain Intra Venous Line with Normal Saline or Ringer's Lactate, give medication/s:

Drug	Dose and route	Continuing dose	Maximum dose	Precautions and contraindications
Oxytocin	IM 10u/IV 20u in 1000 ml NS at fastest flow possible	IV 20u in 1000ml at 40 drops / min	Not more than 3 litres of IV fluids containing Oxytocin	Do not give IV bolus
Ergometrine	IM or IV slowly 0.2mg	Repeat 0.2mg after 15 min if required	5 doses (total 1.0mg)	High BP, Pre-eclampsia heart disease, retained placenta
Carbatocin (heat stable)	100mcg IM or IV over 1min		140mcg	Asthma Cardiac disease
Carboprost	0.25mg IM, every 15-90min, 8 doses maximum (can be used as intramyometrial)		2mg	Asthma Heart Disease*
Do not give Prostaglandins IV				
Misoprostol (Pg E1)	Sublingual 800mcg	Repeat 200-800mcg	Max 1600mcg	
Prostaglandin F2a	IM 0.25mg	0.25mg Every 15mins	Total 8 doses (2mg)	Asthma
Tranexamic acid	1g IV slow over 10mins	Repeat after 30mins if bleeding continues	Not more than 10mg/kg body wt 3-4 times daily	No benefit after 3hrs (may harm) H/O of Coagulopathy, IV clotting, convulsions

- Severe anaemia, especially in later pregnancy or if accompanied by cardiac failure.

Prescribing blood

Prescribing decisions should be based on national guidelines on the clinical use of blood,¹⁴ taking the woman's needs into account. Women with positive blood group (A, B, AB+) can be transfused uncross matched O +ve and Negative group (A, B, AB-) can be transfused O negative blood group in case of life-threatening conditions, instead of waiting for 2 hours for getting cross-matched blood to arrive.

Before prescribing blood or blood products for a woman, keep in mind the following:

- Expected improvement in the woman's clinical condition;
- Methods to minimize blood loss to reduce the woman's need for transfusion
- Alternative treatments that could be given, including IV replacement fluids or oxygen, before making the decision to transfuse;
- Specific clinical or laboratory indications for transfusion;
- Risks of transmitting HIV, hepatitis, syphilis or other infectious agents through the blood products that are available;
- Benefits of transfusion versus risk for the particular woman;
- Other treatment options if blood is not available in time;
- The need for a trained person to monitor the woman and immediately respond if a transfusion reaction occurs.

Monitoring the transfused woman

For each unit of blood transfused, monitor the woman at the following stages:

- before starting the transfusion;
- at the onset of the transfusion;
- 15 minutes after starting the transfusion
- at least every hour during the transfusion;

Intravenous replacement therapy

IV replacement fluids are the first-line treatment for hypovolaemia. Initial treatment with these fluids may be life-saving and can provide some time to control bleeding and obtain blood for transfusion if it becomes necessary. Hypotension should be corrected in ALL especially in Anaemic women, as it may kill them.

Crystalloid fluids

Crystalloids contain a similar concentration of sodium as

in plasma, cannot enter cells because the cell membrane is impermeable to sodium; and pass from the vascular compartment to the extracellular space (normally only a quarter of the volume of crystalloids infused, remains in the vascular compartment).

To restore circulating blood volume (intravascular volume), infuse crystalloids in a volume at least 3 times the volume lost.

Colloid solutions

There is a very limited role for colloids in resuscitation, and they are more expensive than crystalloids

- Colloid particles that are larger than crystalloids and tend to remain in the blood where they mimic plasma proteins to maintain or raise the colloid osmotic pressure of blood.
- Colloids are usually given in a volume equal to the blood volume lost. In many conditions where the capillary permeability is increased (e.g., trauma, sepsis), leakage out of the circulation will occur and additional infusions will be necessary to maintain blood volume.
- There is no evidence that colloid solutions (albumin, dextrans, gelatins, hydroxyethyl starch solutions) have advantages over normal saline or balanced salt solutions for resuscitation.
- There is evidence that colloid solutions may have an adverse effect on survival.
- Human plasma should not be used as a replacement fluid. All forms of plasma carry a risk, similar to that of whole blood, of transmitting infection, such as HIV and hepatitis.
- Plain water should never be infused intravenously. It will cause haemolysis and probably be fatal.

Maintenance fluid therapy

Maintenance fluids are crystalloid solutions, such as dextrose or dextrose in normal saline, used to replace normal physiological losses through skin, lungs, faeces and urine. If it is anticipated that the woman will receive IV fluids for 48 hours or more, infuse a balanced electrolyte solution (e.g. potassium chloride 1.5 g in 1 L IV fluids) with dextrose. The volume of maintenance fluids required by a woman will vary, particularly if the woman has fever or if the ambient temperature or humidity is high, in which case losses will increase.

Prophylactic antibiotics

Performing certain obstetrical procedures (e.g., caesarean birth, manual removal of placenta) increases a woman's risk of infectious morbidity. This risk can be reduced by:

- following recommended infection prevention and

control practices and

- providing prophylactic antibiotics at the time of the procedure.

Whenever possible, give prophylactic intravenous antibiotics 15–60 minutes before the start of a procedure to achieve adequate blood levels of the antibiotic at the time of the procedure. One dose of prophylactic antibiotics (Co-Amoxyclav 1.2 g or Amoxicillin 500mg + metronidazole 500 mg IV or Cefuroxime 750 mg IV or Cephadrine 500 mg IV) is sufficient and is no less effective than three doses or 24 hours of antibiotics for preventing infection after an obstetrical procedure. If the procedure lasts longer than six hours or blood loss is 1500 mL or more, give a second dose of prophylactic antibiotics to maintain adequate blood levels during the procedure.

Obstetrical procedures for which antibiotic prophylaxis is recommended for the woman include the following:

- elective and emergency caesarean (note: prophylaxis to be given before starting the skin incision whenever possible)
- suturing of third- and fourth-degree genital tears
- manual removal of the placenta
- placement of uterine balloon tamponade.¹⁵

Symptoms and signs of shock

Diagnose shock if the following symptoms and signs are present:

- fast, weak pulse (>110 beats per min);
- low BP (systolic BP < 90 mmHg).
- pallor (especially of inner eyelid, palms or around mouth);
- sweating or cold, clammy skin

- rapid breathing (> 30 breaths per minute)
- anxiety, confusion or unconsciousness (“ghabrahat”)
- scanty urine output (<30 mL per hour).

Specific management

- Start an IV infusion (two if possible) using a large-bore (14 or 16-gauge or largest available) cannula / needle.
- Do not give fluids by mouth to a woman in shock
- Collect blood for estimation of haemoglobin, immediate cross-match and bedside clotting test, just before infusion of fluids
- Rapidly infuse IV fluids (normal saline or Ringer’s lactate) initially at the rate of 1 L in 15–20 minutes.
- Give at least 2 L of these fluids in the first hour. This is over and above fluid replacement for ongoing losses.

Note: A more rapid rate of infusion is required in the management of shock resulting from bleeding. Aim to replace two to three times the estimated fluid loss.

- Continue to monitor vital signs (every 15 minutes) and blood loss.
- Catheterize the bladder and monitor fluid intake and urine output
- Give oxygen at 6–8 L per minute by mask or nasal cannula
- If available, apply a non-pneumatic anti-shock garment (NASG) as a temporizing measure until appropriate care is available and /or UBT.

Blood transfusion

- There are no firm criteria for initiating blood transfusion. The decision should be based on both clinical and haematological assessment.

Early recognition of Shock (reduced tissue perfusion) in PPH

Note: Changes in vital signs appear late (>1000 mls bld loss)

Shock Index (SI)

- Heart Rate: Systolic BP
- 0.7 – 0.9 (standard Obstetric)
- 0.5 - 0.7 (non pregnant)
- >0.9 =haemodynamic instability
 - Increased mortality
- >1 = Blood Tx increased risk

Rule of 30

- Loss of 30% blood vol
 - 70mls/kg adults
 - 100 mls/kg pregnant women
- 30% fall in Haematocrit
- 30% fall in Hb (3 g/dl)
- 30 mmHg fall in Systolic BP
- 30 beats/min rise in pulse

FIGO recommends use of Shock Index in Diagnosis & Management of PPH

Figure-6: Early recognition of Shock with Shock Index and Rule of 30

- Fresh whole blood is rarely available in blood banks and Cross matching takes over 1 hour
- Group specific blood can be used
- Major obstetric haemorrhage protocols must include the provision of emergency blood with immediate issue of group O-negative and K-negative units, with a switch to group-specific blood as soon as feasible
- <0.1% risk of transfusion reaction if no abnormal antibodies detected ante-natally
- 1% risk of reaction if Group Specific blood used without screening
- O-neg only when group specific blood not available (possible sensitization to "C" antigen)
- All delivery units, especially small units without a blood bank on site, should maintain a supply of group O, RhD-negative blood
- Cryoprecipitate has more fibrinogen than FFP but lacks Antithrombin III (coagulation inhibitor). Used in profound hypofibrinogenaemia
- Platelet packs (shelf life 5 days) are rarely needed (if count < 50x10/L)
- Factor VII A (not recommended)
- Consider CVP line

Bedside clotting test

- Assess clotting status using this bedside clotting test (if coagulopathy is suspected):
- Take 2 mL of venous blood into a small, dry, clean, plain glass test tube (approximately 10 mm x 75 mm).
- Hold the tube in a closed fist to keep it warm ($\pm 37^\circ$).
- After four minutes, tip the tube slowly to see if a clot is forming. Then tip it again every minute until the blood clots and the tube can be turned upside down.
- Failure of a clot to form after 7 minutes or a soft clot that breaks down easily suggests coagulopathy.

If the woman's condition improves:

- Adjust the rate of infusion of IV fluids to 1 L in six hours.
- Continue management for the underlying cause of shock

If the woman's condition fails to improve or stabilize:

- Continue to infuse IV fluids, adjusting the rate of infusion to 1 L in 6 hours, and maintain oxygen at 6–8 L per minute.
- Closely monitor the woman's condition.
- Perform laboratory tests, including repeat haemoglobin determination, blood grouping and Rh typing, serum electrolytes and creatinine and blood pH.

Facility Emergency Preparedness:

- Keep emergency treatment packs/ boxes ready in emergency trolley or cupboard

- Emergency Pack for PPH Contents:
- IV Fluids 2L (N/S or RL)
- IV Cannula 14 G or 16 G (X2)
- Blood giving set/ IV giving set
- Specimen tubes (Group/cross match)
- Foley's catheter
- Sterile Gloves
- Uterine Balloon Tamponade (UBT) kit
- DRUGS
- OXYTOCIN 20 U (x2 doses)
- ERGOT 0.2mg (x 2 doses)
- MISOPROSTOL 1000 mcg (4 tabs)
- Tranexamic Acid (1g) x 2 doses

Emergency procedures

Bimanual uterine compression or external aortic compression for the treatment of PPH due to uterine atony after vaginal birth is recommended as a temporizing measure until appropriate care is available

UBT (Uterine Balloon Tamponade)

If women do not respond to uterotonic, or if uterotonic




Figure-7: Bimanual uterine compression.




Figure-8: Aortic compression

are unavailable, the use of uterine balloon tamponade (UBT) is recommended as an effective nonsurgical technique that can potentially improve survival in women with PPH due to uterine atony after ruling out retained products of conception or uterine rupture as a contributing factor. Uterine balloon tamponade (UBT) is an effective nonsurgical technique that when employed rapidly by a properly trained person with a proven device in the context of quality PPH care (the PPH bundle) improves survival of women with refractory PPH. Examples of various UBTs are given below from commercially available (Ellavi) and those easily assembled with Condoms/gloves, rubber bands/suture tie, IV giving set/Foley's catheter.¹⁵ (WHO MCPC 2017)




Figure-9: Simplified UBT for Pakistan



Figure-10: Ellavi UBT Kit

Assembling the UBT: (wear sterile gloves to assemble on a sterile tray/ sheet/ paper)

- Assistant removes the IV giving set, condom out of the packaging and deposits on a sterile surface.
- Roll out the condom completely
- Remove the needle and its cap from the IV giving set (not required)
- Assistant will attach the 500ml Mineral water bottle or normal saline IV infusion with the other end of the IV giving set, run the water/ saline in the tubing till end then close the valve on the IV giving set
- Insert the end of giving set from where the needle has been removed into the condom
- Secure the condom on the rigid portion of the IV giving set (Avoid the soft flexible tubing of the IV giving set)
- Twist one rubber band 4 times (or place a sterile suture tied with surgeon's knot) around the condom on the rigid hub of IV giving set

Placement of UBT

- Catheterize and retain Foley's catheter for emptying bladder and monitoring urine output (if not already in place)
- Press the uterine fundus downwards slightly to align it with the cervix and vagina, to make the insertion easier
- After all aseptic measures insert a Sim's speculum and retract the posterior vaginal wall
- Use iodine disinfectant cotton swab, or povidone iodine solution to gently wipe the entire surface of the condom and rubber band
- Visualize the cervix and hold the anterior lip of the cervix with a sponge forceps
- Hold the condom of the assembled UBT with another Sponge forceps or between index and middle finger and insert the condom into the middle of the uterine cavity
- Hold up the Normal saline infusion bag or Mineral water bottle and open the valve of the IV giving set on full flow
- Fill the condom with 300- 500ml of mineral water or normal saline until the inflated balloon becomes visible in the cervical canal, and bleeding stops (when balloon pressure exceeds patient's BP)
- Once the bleeding stops close the valve of the IV giving set, so no more fluid enters the condom
- Fix the tubing of the IV giving set to the patient's thigh with an adhesive tape
- Uterine fundus is palpated and a mark is made on the abdomen to monitor for any further uterine distention indicating ongoing bleeding

- Keep uterus contracted with IV infusion of 40 units oxytocin in 500 mls of normal saline given over 8 hours
- If considerable resistance is felt while inflating the balloon and bleeding persists, pause fluid instillation and re-examine balloon placement to ensure that it is correctly placed inside the uterus and that there are no other sources of bleeding.

Monitoring

- Once bleeding stops, the patient is ready for careful observation or transfer to a referral facility. The UBT device should stay in place for at least 6-24 hours and should always be kept in place during transfer.
- Monitor the patient continuously for signs of increased vaginal bleeding, pulse, Blood Pressure, fundal height, temperature and urine output
- A prophylactic dose of antibiotic (e.g. Amoxicillin-clavulenic acid, Metronidazole) is recommended.
- Give appropriate IV fluids or blood replacement products until she is stable and not bleeding heavily
- Worsening clinical signs and symptoms should lead to more aggressive treatment and management

UBT Removal

The timing of balloon removal should be decided by senior clinicians once the patient is stabilized.

- Keep the patient fasting, when removal is planned, in case the patient starts to bleed and anaesthesia is required
- Put the IV infusion bottle on a lower level than the patient and open the valve of the IV giving set and remove 50-100 ml of fluid from the condom balloon, then close it again
- Observe for 30 –60 minutes for return of bleeding. Re-inflate if bleeding resumes. If bleeding remains arrested, fully deflate the condom by removing all the fluid from it
- Remove the adhesive tape on thigh and UBT device from the patient's uterus and vagina by pulling it out
- Continue 20 units oxytocin infusion for another 12-24 hrs to keep uterus well contracted

Warnings

- UBT is a single use disposable device
- Avoid excessive force when inserting the balloon into the uterus
- Use of this device should not delay appropriate application of other critical interventions such as uterotonics, blood products, angiography and/or surgery.
- Avoid leaving the UBT indwelling for more than 24 hours (Senior clinicians to decide)
- The balloon should never be inflated with air, carbon

dioxide, or any other gas.

- Use 500 mls maximum inflation of the condom balloon

Uterine Vacuum Tamponade (UVT) is an alternative to UBT showing efficacy in reported trials. Suction tamponade has been shown to be beneficial in prospective studies and are being studied in larger trials.¹⁶ It is an intrauterine balloon catheter (like Foley's) filled with 70 mL of solution, to apply intrauterine vacuum. Vacuum-induced tamponade helps to suck blood from the uterine cavity and supports uterine contraction, leading to a coiling of the spiral arteries and reduced blood loss.¹⁶

Non-pneumatic anti-shock garment (NASG) use is recommended as a temporizing measure until appropriate care is available. The non-pneumatic anti-shock garment (NASG) is an effective nonsurgical device that should be in every healthcare facility. The NASG, when used as a temporizing measure to recover haemodynamic stability in the context of PPH, decreases morbidity, mortality, and hypovolaemic shock, and is of special importance in a LMIC (Low middle income countries) like Pakistan

Uterine packing is not recommended for the treatment of PPH due to uterine atony after vaginal birth

Uterine artery embolization can be another conservative management for PPH if technical conditions and skilled human resources are available for its use. Interventional radiology may be indicated for the prevention and treatment of PPH either before delivery, in cases of known placental abnormalities and implantation (Placenta Accreta/ percreta), or after delivery when the patient is haemorrhaging. Prophylactic catheterization of the






Figure10: UBT Preparation kit: Source WHO MCPC 2017¹⁵

uterine arteries, with embolization, can be considered an important therapeutic strategy that is safe and effective for reducing maternal and fetal morbidity and mortality by controlling blood loss.

Surgical interventions are recommended if bleeding does not stop despite using uterotonics and other available conservative interventions (e.g. uterine massage, balloon tamponade). Surgical interventions include compression suture techniques, uterine and hypogastric artery ligation, and hysterectomy.

Stop bleeding before the patient develops coagulation problems and organ damage from under-perfusion. Conservative approaches should be tried first, rapidly moving to more invasive procedures if these do not work. For additional details of surgical procedures refer to WHO MCPC Manual.¹⁵

Obstetricians must quickly recognize the onset of PPH, safely administer uterotonics, and place emergent




Figure-12: B-Lynch Suture.




Figure-13: Simplified Brace Suture




Figure-13: Bilateral Uterine & Ovarian Artery Ligation

compression sutures if needed. In the immediate postoperative period, women should be monitored for complications such as haematometra, pyometra, and uterine synechiae. Most important is the ability of the obstetrician to control bleeding using medical and surgical interventions, stabilize the mother, and reduce maternal morbidity.

When medical treatment fails to control the bleeding, several surgical options exist. To date, no randomized controlled trials have assessed these techniques, nor compared the superiority of one to another, and all the data are based on case reports and case series. The use of these methods largely depends on the healthcare facilities and on the care providers' clinical skills.

Better and regular training of all care providers in these life-saving techniques, should be conducted. Future fertility following these procedures remains under-assessed due to the lack of long-term follow-up. More research should target these surgical techniques to avoid the more morbid procedures, to improve maternal and perinatal outcomes.

Detailed description of these surgical procedures can be found in the WHO MCPC Manual (2017) updated Pakistan Edition 2023 in print.¹⁷

Damage control resuscitation (DCR) and Damage Control Surgery (DCS) for refractory severe PPH, is a combination of resuscitation and surgical interventions with the purpose of restoring haemostasis and normal physiology. These techniques have proven to be applicable in obstetrics, with satisfactory results controlling refractory PPH with an overall decreased mortality of critically ill patients, especially in patients in whom conventional treatment can be linked to a high risk of failure. DCS is an available therapeutic approach for the management of severe PPH, thus proper training must be widespread to implement this technique.⁶ (Figo 2022)

Basic recommendations for resuscitation in PPH: (Figo 2022)

- Administration of crystalloids in small boluses of 500 ml, checking clinical signs and looking for improvement. Balanced crystalloid solutions such as Ringer's lactate is preferred over chlorine-rich solutions.
- The target blood pressure in hypotensive resuscitation is 80–90 mm Hg for systolic blood pressure or 50–60 mm Hg for mean blood pressure.
- In haemostatic reanimation, fewer crystalloids are administered and, instead, blood replacement is started earlier with high ratios of transfusion of Packed cells: FFP: Platelets (1:1:1) OR give Whole Blood transfusion
- During massive transfusions, the target for serum fibrinogen is 150–200 mg/dl and the usual dose of cryoprecipitate is 10 units; it is estimated that these will raise the serum fibrinogen by 100 mg/dl.
- Massive transfusion Protocol (MTP) should be in place at each institution. For every 4 units of packed red blood cells, 15 ml/kg Fresh Frozen Plasma (FFP) is given. Physicians should be familiar with their hospitals' protocol and recommendations.
- Develop a MTP for your institution. It should be initiated when there is loss of 50% of blood volume, or 4 units of packed cells have been transfused, or there is haemodynamic instability with profuse bleeding.^{6,17}

Massive Transfusion Protocol (MTP) Checklist:

- Create your own MTP. Establish a working group with nearest blood bank, and other stakeholders
- Establish rapid communication between Obstetric ward and Blood banks
- Essential lab testing and rapid reporting
- Have O-ve blood always available and group specific blood, know what is available
- Rapid transport of blood and products
- Ensure Emergency trolley with PPH kits, supplies for lab work and blood administration is available in every labour ward
- Regular training and re-training of Providers (e.g x 6 monthly)
- Clear communication with the patient's family about giving blood (and its products)

Implementation of the recommendations by health systems and national societies for the management of PPH in Pakistan

- All national societies must lobby and work with the Government to reduce maternal mortality and

morbidity due to PPH in Pakistan, and work with their respective regional and national organizations to promote and implement these recommendations.

- Aim to establish a PPH bundle approach and make the medical supplies and surgical equipment needed for the management of PPH readily available, added to the essential medicines/ equipment list, in all regions of Pakistan.
- **Audit newsletters:** Sharing with all staff monthly rates of detection and bundle use, along with rates of PPH, severe PPH, blood transfusion, laparotomy, and death from PPH and giving feedback at monthly departmental meetings
- **Champions:** Midwife and doctor to oversee change, troubleshoot, give feedback on audit newsletters, connect with other champions by means of chats, meetings, and websites for sharing knowledge and lessons learned
- **Trolley or carry case:** Restocking of all medicines and devices used for treatment of PPH after every use and completion of a stocking checklist at the start of every shift Training: Barriers and gaps can be addressed through providing an enabling environment through supportive policies, designing a formal plan for supplies, task shifting strategies, and use of guidelines and protocols for successful implementation.
- Regular Onsite Simulation based training, peer assisted, facilitated with provider guides, flipcharts, and job aids displayed in labour wards
- Each hospital should have a Protocol on the management of PPH and Massive Blood Transfusion, Referral Network Integration, record keeping and audit
- NCMNH, AMAN, MAP and other OBGYN organisations like SOGP, in Pakistan working on maternal and Child Health, should lobby to have the essential medications and equipment that are needed to prevent and treat PPH, readily available in all maternity centres.
- Research is still necessary to improve knowledge on implementation issues for NASG use in refractory PPH management.
- All health systems are obligated to provide respectful care to the woman, the infant, and the associated family. Health systems must provide the appropriate and effective medications, water, oxygen, equipment, training, and transfer mechanisms to save the lives of women and newborns.
- Postpartum contraception (PPIUCD, Implants), and Family Planning Counselling should be part of routine care

- PPH Bundle approach management workshops for all involved in care of pregnant women with government support. This is currently being done by Senior Obstetricians and Gynaecologists (Master Trainers) on a voluntary basis.
 - Training of all HCPs in quality Antenatal care with 8 contact visits; de worming and Antenatal correction of Anaemia with oral and Parenteral iron. This should also be done before discharge home post-partum
 - Medical Supplies should include heat stable Carbetocin, NASG, UBT, Under the buttock Drapes for blood collection, and added to the essential medical supplies list.
 - **Uniform Record keeping:** Obstetric register with additional variables columns including mode of delivery, Active Management of Third Stage of Labour AMTSL, Estimated Blood loss (EBL) Post Partum Family planning (PPFP) Post Partum Intra Uterine Contraceptive Device (PPIUCD/ Implant/ depo progesterone) Newborn information, post-partum monitoring. As recently developed by WHO:
 - Regular central reporting of data to the Provincial and National Health departments
 - Implement standard forms for referral to secondary and tertiary care centres
 - PPH Bundle approach training and certification should be mandatory in undergraduate and postgraduate training curriculum.
- **The Ministry of Health (MOHRSC) should facilitate local manufacturing of:**
 - Carbetocin (heat stable utero tonic with efficacy comparable to Oxytocin)
 - Cost effective UBT kits (like Ellavi)
 - NASG Anti shock garment
 - Under buttock plastic blood collection drape (preferably biodegradable plastic) for measuring blood loss.


References

1. National Institute of Population Studies (NIPS) Pakistan, International Coaching Federation (ICF). Pakistan Maternal Mortality Survey 2019: Key Indicators Report. Islamabad, Pakistan, and Rockville, Maryland, USA: NIPS and ICF; 2020. [Online] 2020 [Cited 2024 January 19]. Available from URL: <https://dhsprogram.com/pubs/pdf/PR128/PR128.pdf>
2. National Institute of Population Studies (NIPS) Pakistan, International Coaching Federation (ICF). Pakistan Demographic and Health Survey 2017-18. Islamabad, Pakistan, and Rockville, Maryland, USA: NIPS and ICF; 2019. [Online] 2019 [Cited 2024 January 19]. Available from URL: <https://dhsprogram.com/pubs/pdf/FR354/FR354.pdf>
3. A Roadmap to combat postpartum haemorrhage between 2023 and 2030. Geneva, Switzerland: World Health Organization; 2023. [Online] 2023 [Cited 2024 January 19]. Available from URL: https://cdn.who.int/media/docs/default-source/reproductive-health/maternal-health/pph-roadmap.pdf?sfvrsn=db36b511_3
4. Ahsan A, Pal SA, Zaki M, Raza F, Samina M, Memon M. In-Depth Analysis of Maternal Deaths. In: Explaining Maternal Mortality: An In-depth Analysis of Pakistan Maternal Mortality Survey 2019. [Online] 2022 [Cited 2024 January 19]. Available from URL: https://ncmh.org.pk/wp-content/uploads/2023/04/31C3C34D-A456-4FAE-9B0C-FE0AB008887C.Predictors_of_Maternal_Mortality_Report_Final.pdf
5. World Health Organization (WHO). WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva, Switzerland: WHO Press; 2012. [Online] 2012 [Cited 2024 January 17]. Available from URL: <https://www.who.int/publications/i/item/9789241548502>
6. Escobar MF, Nassar AH, Theron G, Barnea ER, Nicholson W, Ramasauskaite D, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. *Int J Gynaecol Obstet* 2022;157(Suppl 1):3-50. doi: 10.1002/ijgo.14116.
7. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. *Obstet Gynecol* 2017;130:e168-86. doi: 10.1097/AOG.0000000000002351.
8. Prevention and Management of Postpartum Haemorrhage: Green-top Guideline No. 52. *BJOG* 2017;124:e106-49. doi: 10.1111/1471-0528.14178.
9. The Federation of Obstetric and Gynaecological Societies of India (FOGSI). PPH Prevention and Management: Updated PPH Guidelines. [Online] 2022 [Cited 2024 January 17]. Available from URL: <https://www.fogsi.org/wp-content/uploads/tog/pph-prevention-and-management-updated-sept-2022.pdf>
10. Althabe F, Therrien MNS, Pingray V, Hermida J, Gülmezoglu AM, Armbruster D, et al. Postpartum hemorrhage care bundles to improve adherence to guidelines: A WHO technical consultation. *Int J Gynaecol Obstet* 2020;148:290-9. doi: 10.1002/ijgo.13028.
11. Gallos I, Devall A, Martin J, Middleton L, Beeson L, Galadanci H, et al. Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage. *N Engl J Med* 2023;389:11-21. doi: 10.1056/NEJMoa2303966.
12. Departmental News. Lifesaving solution dramatically reduces severe bleeding after childbirth. News release. The WHO Media Centre. [Online] 2023 [Cited 2023 June 23]. Available from URL: <https://www.who.int/news/item/09-05-2023-lifesaving-solution-dramatically-reduces-severe-bleeding-after-childbirth>
13. Shakur-Still H, Roberts I, Grassin-Delyle S, Chaudhri R, Geer A, Arribas M, et al. Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births. *BJOG* 2023;130:1177-86. doi: 10.1111/1471-0528.17455.
14. Ministry of Health Government of Pakistan. Standards and Guidelines for Blood Transfusion Services (BTS) Pakistan, 1st ed. Islamabad, Pakistan: National Institute of Health (NIH); 1999. [Online] 1999 [Cited 2024 January 24]. Available from URL: <https://nacp.gov.pk/repository/howwework/Technical%20Guidelines/Blood%20Transfusion/Standards%20and%20Guidelines%20For%20Blood%20Transfusion%20Services.pdf>
15. Managing complications in pregnancy and childbirth: a guide for midwives and doctors, 2nd ed. Geneva, Switzerland: World Health Organization; 2017. [Online] 2017 [Cited 2024 January 24]. Available from URL: <https://iris.who.int/bitstream/handle/10665/255760/9789241565493-eng.pdf>
16. Haslinger C, Weber K, Zimmermann R. Vacuum-Induced Tamponade for Treatment of Postpartum Hemorrhage. *Obstet Gynecol* 2021;138:361-5. doi: 10.1097/AOG.0000000000004510.
17. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. *Am J Obstet Gynecol* 2016;214:340-4. doi: 10.1016/j.ajog.2015.08.068.


Appendix - 1

TREAT AND DETECT POSTPARTUM HAEMORRHAGE EARLY


E




M




O




T



IV



E



Early detection and trigger criteria

- Calibrated drape for blood loss collection with trigger lines at **300ml and 500ml** for the first hour after birth
- Observations (blood loss, blood flow, uterine tone) every **15 minutes** documented on the blood loss monitoring chart
- Blood pressure and pulse carried out once in the **1st hour** postpartum and documented on the blood loss monitoring chart

Message of uterus

- Massage until uterus has contracted or for **one minute**

Oxytocic drugs

- **10 IU IV oxytocin injection** or diluted in **200-500ml crystalloid** over **10 minutes** plus a maintenance dose for **20 IU IV oxytocin** diluted in **1000ml saline** over **4 hours** (+ misoprostol 800mcg PR/SL if used)

Tranexamic acid

- **1g IV injection of tranexamic acid** or diluted in **200ml crystalloid** over **10 minutes**

IV fluids

- IV fluids in addition to the infusion should be given if clinically indicated for resuscitation and will require a **2nd IV access**


Examination and escalation

- Ensure bladder is empty, evacuate clots, check for tears with an internal examination and placenta for completeness
- Escalate if bleeding does not stop after first response or you are unable to identify or manage cause of bleeding


Trigger criteria

- 1 Clinical judgement
- 2 Blood loss 500ml or more
- 3 Blood loss 300ml or more plus one abnormal observation


Implementation strategies




Audit newsletters: sharing with all staff monthly detection and bundle use rates along with PPH, severe PPH, blood transfusion, laparotomy and death from PPH rates and given feedback at monthly departmental meetings




Champions: midwife and doctor to oversee change, troubleshoot, give feedback on audit newsletters, connect with other champions through chats, meeting and websites for sharing knowledge and lessons learnt



Trolley and/or carry case: including all medicines and devices required for the treatment of PPH restocked after every use and complete a stocking checklist at the start of every shift



Training: on-site, simulation-based, and peer-assisted training of 90 minutes to a whole day facilitated by the use of provider guides, flipcharts and job aids displayed in labour wards







World Health Organization

PPH Emergency Response

AMTSL CALL FOR HELP!

First Response Bundle


Uterine Massage 	IV Fluids 	Uterotonics 	Tranexamic Acid 
---	---	--	---

SUPPORTIVE MEASURES

Treat tears Empty bladder Empty uterus



Refractory PPH Interventions

Compression 	Uterine Balloon 	Anti-shock Garment 
---	---	---

SUPPORTIVE MEASURES

Transfusion Referral Surgery



11/19/2019

© Copyright 2019-2020 The General Hospital Corporation. Used with permission.

Appendix 2: Best Practices in PPH Prevention and Management

PPH Prevention

- ▶ Anemia prevention and early detection
- ▶ Malaria prevention, detection, and control
- ▶ HIV status and treatment if necessary
- ▶ Identification of previous and current co-morbidities
- ▶ Birth planning and complication preparedness


First Response

- ▶ Early recognition of excessive bleeding
- ▶ Monitor vital signs (pulse, BP, temperature, and respirations), volume and rate of blood flow, level of consciousness or anxiety, skin color, and response to treatments
- ▶ Laboratory Testing for Hgb/HCT, clotting factors (or bedside clotting test), and Type and Cross match
- ▶ If Placenta delivered, was it intact, or is it retained?
- ▶ Reassurance to woman and her family that everything is being done

Response to Refractory PPH

- ▶ Inform woman and her family of treatment options, provide reassurance
- ▶ Continue monitoring for status and development of shock, if shock suspected begin shock management
- ▶ Surgical Management
 - Uterine compression sutures
 - Uterine or utero-ovarian artery ligation
 - Begin with conservative management, try to spare the uterus
 - If woman continues to bleed, perform hysterectomy

Quality PPH Emergency Care



Created by Massachusetts General Hospital Division of Global Health Innovation

Acronyms & Abbreviations:

ACOG	American College of Obstetricians & Gynaecologists
ACS	Antenatal Corticosteroids
AMTSL	Active Management of Third stage of Labour
AJK-	Azad Jammu & Kashmir
ANC	Antenatal Care
AMAN	Association for Mothers & Newborns (Pakistan)
APH	Antepartum haemorrhage
BEmONC	Basic Emergency Obstetric and Newborn Care
CCT	controlled cord traction
CS	Caesarean Section
CEmONC	Comprehensive Emergency Obstetric and Newborn Care
CVP	Central Venous pressure
EBL	Estimated Blood Loss
EmONC	Emergency Obstetric and Newborn Care
FIGO	International Federation of Gynecology and Obstetrics
FOGSI	Federation of Obstetric and Gynecological Societies of India
GB	Gilgit Baltistan
KP	Khyber Pakhtunkhwa
IM	Intramuscular
IV	Intravenous
IVL	Intravenous line
LHWs	Lady Health Workers
LCG	Labour Care Guide
MAP	Midwifery Association of Pakistan
MoNHSRC	Ministry of National Health Services, Regulation and Coordination, Pakistan
NCMNH	National Committee for maternal & neonatal health Pakistan
NICU	neonatal intensive care unit
NICE	National Institute for Health and Care Excellence England (guidelines)
NMR	Neonatal mortality rate
PMMS	Pakistan Maternal Mortality Survey
PDHS	Pakistan Demographic and Health Survey
NS	Normal Saline
PPH	Post Partum Haemorrhage
PPFP	Post Partum Family Planning
PPIUCD	Post Partum Intra Uterine Contraceptive Device
RCOG	Royal College of Obstetricians and Gynecologists
RL	Ringer's Lactate
SDGs	Sustainable Development Goals
SOGP	Society of Obstetricians & Gynaecologists of Pakistan
SRH	[WHO Department of] Sexual and Reproductive Health and Research
TXA	Tranexamic acid
UBT	Uterine Balloon Tamponade
UVT	Uterine Vacuum tamponade
WHO	World Health Organisation